Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Paracetamol + caffeine is a fixed-dose combination of two active ingredients: paracetamol (also known as acetaminophen), an analgesic and antipyretic, and caffeine, a central nervous system stimulant. This combination is primarily used for the short-term relief of moderate pain such as headaches, migraines, muscle aches, menstrual pain, toothaches, backaches, colds and sore throats. Paracetamol works by inhibiting prostaglandin synthesis in the central nervous system or by activating descending serotonergic pathways to reduce pain perception. Caffeine acts as a vasoconstrictor in the brain to reduce headache and also enhances the analgesic effect of paracetamol[1][2][5]. The combination provides more effective symptom management than either agent alone.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on paracetamol + caffeine.